Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2019 | FORWARD I: mirvetuximab soravtansine vs chemo in platinum-resistant ovarian cancer

Kathleen Moore • 29 Sep 2019
ESMO 2019
Gynecological Cancer Ovarian Cancer Antibodies Mirvetuximab soravtansine
FORWARD I

Kathleen Moore, MD, Stephenson Cancer Center, Oklahoma City, OK, talks about the FORWARD I Phase III study of mirvetuximab soravtansine (NCT02631876), a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), versus chemotherapy in patients with platinum-resistant ovarian cancer (PROC). This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

More from Kathleen Moore

3:45
PARP inhibitors for ovarian cancer
Kathleen Moore • 30 Sep 2019
3:58
SOLO-1: practice changing data on olaparib for ovarian cancer
Kathleen Moore • 19 Oct 2018
2:27
The PAOLA-1 study: olaparib and bevacizumab for ovarian cancer
Kathleen Moore • 19 Oct 2018
7:39
Ovarian news from ESMO 2018: SOLO-1 results for olaparib
Kathleen Moore • 21 Oct 2018

Related Videos

0:39
Early diagnosis of ovarian cancer with Pap smears
Sergio Marchini • 8 Apr 2024
0:46
FRa expression and sequencing ADCs in endometrial cancer
Rebecca Porter • 8 Apr 2024
4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:11
Clonal hematopoiesis mutations in ovarian carcinomas
Rebecca Porter • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals